Remoxy Time Release Oxycodone Phase III Trial Planned For Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Pain Therapeutics says drug is bioequivalent to Oxycontin and will consider filing under ANDA pathway. Labeling may contain fewer drug abuse warnings compared to Oxycontin.